Former Chief Operating Officer and General Counsel · Kronos Bio, Inc. (KRON)

Barbara Kosacz

FY2023 is the first fiscal year CompBrief holds for Barbara Kosacz as a named executive officer of Kronos Bio; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,306,466

Salary $470,000Stock awards $290,324Bonus $45,000

2nd of 3 named executive officers at Kronos Bio by FY2023 total.

3 named officers on file for Kronos Bio, FY2023

Barbara Kosacz’s pay file — $29

  • 1 fiscal year of pay, line by line
  • KRON’s disclosed peer group of 24 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kronos Bio’s whole pay program stands against its peers

  • Kronos Bio’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KRON→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Barbara Kosacz’s full pay file as a PDF — free

More than this page: up to 10 years of Barbara’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Barbara Kosacz compensation by year

Kronos Bio Summary Compensation Table · the one fiscal year held
In US dollars, as Kronos Bio reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$470,000
Bonus$45,000
Stock awards$290,324
Option awards$310,008
Non-equity incentive$188,000
Pension and deferred compensation$0
All other$3,133
Total$1,306,466

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kronos Bio, Inc. DEF 14A filed April 29, 2024, accession 0001140361-24-023006, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kronos Bio, Inc. filed document, accession 0001140361-24-023006. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU138,911$173,639—
RSU41,876$77,350—
RSU35,734$44,668—
RSU20,004——
Option43,334—$7.08
Option164,958—$2.09
Option26,184—$30.94

Per the Outstanding Equity Awards at Fiscal Year-End table in Kronos Bio, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments Kronos Bio discloses, by trigger · FY2023
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$364,482$130,173$26,352$521,007

Per the Potential Payments Upon Termination or Change in Control table in Kronos Bio, Inc.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.

Kronos Bio’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Norbert BischofbergerPresident and Chief Executive Officer$1,761,537
Barbara Kosacz · this pageFormer Chief Operating Officer and General Counsel$1,306,466
Jorge DiMartinoFormer Chief Medical Officer and Executive Vice President, Clinical Development$1,286,684

The full Kronos Bio compensation record

free company brief

This page is one person within Kronos Bio's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kronos Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Barbara Kosacz's compensation dossier · One-time report. No refunds.